Delivery Order SPE2DB24D2101-SPE2DB25FKLAN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $25,144.81 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on June 16, 2025, with completion scheduled for June 17, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $42,441.91. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory and allergic conditions,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency awarded a $21,060.94 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-competitive, firm fixed price delivery order is expected to be completed by July 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,291.75 for Dupixent 300 mg/2 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma,...
- The Defense Logistics Agency awarded a $40,995.34 delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, non-set-aside contract specifies firm fixed pricing with an ultimate completion date of April 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $8,504.17 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $11,823.41 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 6, 2025, with completion scheduled for August 7, 2025. This firm fixed-price, non-set-aside contract will be performed at the awardee's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis,...
- The Defense Logistics Agency awarded a delivery order valued at $17,508.38 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed-price delivery order, issued without set-aside designation, is fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKLANDelivery Order
The Defense Logistics Agency awarded a $31,497.66 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by June 3, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various allergic and inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen serves military and veteran healthcare systems through the DLA Medical Supply Chain. The company's portfolio encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic areas, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this comprehensive global pharmaceutical support vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.5k | 6/2/25 |